Published in Lab Invest on May 16, 2016
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Neuroblastoma. Lancet (2007) 10.61
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (1994) 10.22
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell (1995) 9.22
MYC on the path to cancer. Cell (2012) 8.65
c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol (1999) 8.17
Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol (1998) 7.43
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J (1998) 6.94
IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity (2002) 6.85
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res (1993) 6.31
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci U S A (1989) 2.92
TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev (2008) 2.72
p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol (2005) 2.65
Apoptotic signaling by c-MYC. Oncogene (2008) 2.57
bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res (1995) 2.56
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal (2010) 2.27
E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell (2002) 2.20
The role of c-myc in cellular growth control. Oncogene (1999) 2.14
Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer (1997) 1.94
Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev (2005) 1.80
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol (2000) 1.74
Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. J Biol Chem (2007) 1.72
Action of Myc in vivo - proliferation and apoptosis. Curr Opin Genet Dev (2000) 1.69
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol (2008) 1.64
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med (2010) 1.47
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A (2012) 1.46
Neuroblastoma: biology and staging. Curr Oncol Rep (2009) 1.40
c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene (2013) 1.29
DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci U S A (1996) 1.22
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer (2010) 1.18
C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer (2007) 1.11
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res (1995) 1.05
β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death Differ (2014) 1.00
Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol (2008) 0.97
Poly(ADP-ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci (2005) 0.96
TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol (2009) 0.93
Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol (2013) 0.93
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol (2012) 0.92
Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. Anticancer Res (2006) 0.92
Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol Immunol (2010) 0.90
Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci U S A (2013) 0.90
Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. J Biomed Sci (2011) 0.87
Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther (2014) 0.85
Both cell-autonomous and cell non-autonomous functions of GAP-43 are required for normal patterning of the cerebellum in vivo. Cerebellum (2008) 0.84
Induction of c-Myc-dependent cell proliferation through toll-like receptor 3 in head and neck cancer. Int J Mol Med (2008) 0.84
Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol (2001) 0.83
Altered phosphorylation of growth-associated protein B50/GAP-43 in Alzheimer disease with high neurofibrillary tangle density. Proc Natl Acad Sci U S A (1993) 0.80
Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Lett (2013) 0.79
P-GAP-43 is enriched in horizontal cell divisions throughout rat cortical development. Cereb Cortex (2006) 0.78
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Mol Cancer (2014) 0.78
Preferential involvement of mitochondria in Toll-like receptor 3 agonist-induced neuroblastoma cell apoptosis, but not in inhibition of cell growth. Apoptosis (2012) 0.78
MDA5 complements TLR3 in suppression of neuroblastoma. Oncotarget (2015) 0.76
B4GALNT3 expression predicts a favorable prognosis and suppresses cell migration and invasion via β₁ integrin signaling in neuroblastoma. Am J Pathol (2011) 0.97
GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Int J Cancer (2005) 0.91
Aryl hydrocarbon receptor downregulates MYCN expression and promotes cell differentiation of neuroblastoma. PLoS One (2014) 0.81
MDA5 complements TLR3 in suppression of neuroblastoma. Oncotarget (2015) 0.76
A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients. Oncotarget (2016) 0.75